Abstract
Abstract
Objective
To report the pregnancy outcomes on patients with chronic migraine exposed to onabotulinumtoxinA from Hull Headache Clinic.
Background
Migraines are common in women of reproductive age and those with chronic migraine have a major impact on their activities of daily living and health-related quality of life. Apart from low dose amitriptyline and beta-blockers all other prophylactic agents have proven teratogenic effects. OnabotulinumtoxinA is approved as preventive treatment for adult patients with chronic migraine, although its impact on pregnancy is unknown.
Methods
We prospectively collected data for efficacy and safety on all patients treated with onabotulinumtoxinA at the Hull Headache Clinic. The toxin is administered as per PREEMPT paradigm. Female patients of reproductive age group receiving onabotulinumtoxinA are given advice on contraception and the unknown impact of the toxin on pregnancy. They are asked to report pregnancy when they are appraised on the risk/benefit of treatment continuation. All patients are consented for access to their medical records and pregnancy outcome and those who wished to continue are asked to sign a disclaimer. Pregnancy outcome data was collected on all patients for the mode of delivery, birth weight and congenital malformation and any other unexpected outcomes.
Results
Over 9 years period 45 patients reported pregnancy while receiving onabotulinumtoxinA. All patients had received onabotulinumtoxinA within 3 months prior to the date of conception. 32 patients wished to continue treatment during pregnancy while the remaining 13 stopped treatment. Apart from 1 miscarriage in the treatment group, all patients had full term healthy babies of normal birth weight and no congenital malformations.
Conclusion
We report our experience of 45 patients exposed to onabotulinumtoxinA during pregnancy. Although the numbers are small, there was no impact of the toxin found on the pregnancy outcomes.
Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine,Clinical Neurology,General Medicine
Reference21 articles.
1. Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, Terrin A, Reuter U (2017) D D Mitsikotas on behalf of the European headache federation school of advanced studies. Headache Pregnancy 18:106
2. MacGregor A (2009) Management of migraine during pregnancy. Prog Neurol Psychiatry 13(5):21–24
3. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R et al (2006 Feb) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry 77(2):193–198
4. NICE[TA260] (2012) Botulinum toxin type a for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance Accessed on 30 Sept 2020
5. Robinson AY, Grogan PM (2014) OnabotulinumA successfully used as a migraine prophylaxis during pregnancy: a case report. Mil Med 179(6):703–704
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献